USClinicalTrials.govClinical trialPhase 2/3Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Official record
- Identifier
NCT06989437- Recruiting locations
countries
United StatesAustraliaBelgiumBrazilBulgariaCanadaChinaFranceGermanyIndiaIsraelItalyJapanMexicoPolandPuerto RicoSlovakiaSouth KoreaSpainTaiwanUnited Kingdom- Interventions studied
- ponsegromabplacebo
- Lead sponsor
- Pfizer
- Target enrolment
- 982 participants
- Study type
- INTERVENTIONAL
- Phase
- Phase 2/3
- Status
- Recruiting
- First posted
- May 25, 2025
- Last updated on the registry
- Sep 25, 2026
- Age
- 18 Years
- Sex
- ALL
- Study contact
- The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.
- Eligibility criteria
Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.
Key inclusion Criteria: * Signed Informed Consent Document * Documented active diagnosis of metastatic pancreatic ductal adenocarcinoma * Cachexia defined by Fearon criteria of weight loss * Completed 1 x 28-day cycle of first-line systemic nab-paclitaxel and gemcitabine chemotherapy or 2 x 14-day cycles of FOLFIRINOX chemotherapy and prior to receiving Cycle 2 chemotherapy * ECOG PS ≤1 with life expectancy of at least 4 months Key Exclusion Criteria: * Current active reversible causes of decreased food intake * Cachexia caused by other reasons * Any prior or current clinical diagnosis of heart failure, irrespective of left ventricular ejection fraction or New York Heart Association classification * Left ventricular ejection fraction \<50% * Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization * History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody * History of allergy or hypersensitivity to any of the chemotherapeutics or any of their excipients * Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma, symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases * Inadequate liver function * Renal disease requiring dialysis or eGFR \<30 mL/min/1.73m2
- Indexed under
- Pancreatic Cancer